Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Spinal Cord Ser Cases ; 6(1): 69, 2020 08 04.
Article in English | MEDLINE | ID: mdl-32753638

ABSTRACT

STUDY DESIGN: Observational case-control study. OBJECTIVE: Individuals with spinal cord injury (SCI) develop systemic physiological changes that could increase the risk of severe evolution of coronavirus disease 2019 (COVID-19) and result in atypical clinical features of COVID-19 with possible delay in both diagnosis and treatment. We evaluated differences in clinical features and evolution of COVID-19 between people with SCI and able-bodied individuals. SETTING: The study was conducted in an Italian inpatient rehabilitation referral center for individuals with SCI during the lockdown for the COVID-19 pandemic. METHODS: We compared clinical information between patients with SCI and able-bodied healthcare workers of the same center who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the nasopharyngeal swab polymerase chain reaction. RESULTS: Overall, 15 out of the 25 SCI patients admitted to the center and 17 out of the 69 healthcare workers tested positive for SARS-CoV-2. Patients with SCI exhibited a significantly more advanced age and a higher prevalence of comorbidities. Nevertheless, no significant differences in clinical expression of COVID-19 and treatment strategies were observed between the two groups. All hospitalized subjects were treated in nonintensive care units and no deaths occurred in either group. CONCLUSIONS: This study does not support the supposed notion that COVID-19 could exhibit atypical clinical features or a worse evolution in the frail population of people with SCI.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Anticoagulants/therapeutic use , Antiviral Agents/therapeutic use , Coronavirus Infections/therapy , Hydroxychloroquine/therapeutic use , Oxygen Inhalation Therapy , Pneumonia, Viral/therapy , Spinal Cord Injuries/physiopathology , Adult , Aged , Azithromycin/therapeutic use , Betacoronavirus , COVID-19 , Case-Control Studies , Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Coronavirus Infections/physiopathology , Drug Combinations , Enzyme Inhibitors/therapeutic use , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Italy , Lopinavir/therapeutic use , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/physiopathology , Prognosis , Rehabilitation Centers , Ritonavir/therapeutic use , SARS-CoV-2 , Spinal Cord Injuries/complications , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL
...